ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

GSK Gsk Plc

1,708.60
3.40 (0.20%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Gsk Plc LSE:GSK London Ordinary Share GB00BN7SWP63 ORD 31 1/4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.40 0.20% 1,708.60 1,708.60 1,708.80 1,713.00 1,699.40 1,701.60 11,102,455 16:29:59
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 30.33B 4.93B 1.1970 14.27 70.34B

GlaxoSmithKline PLC GSK confirms start date for Luke Miels (5167I)

19/06/2017 4:29pm

UK Regulatory


Gsk (LSE:GSK)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Gsk Charts.

TIDMGSK

RNS Number : 5167I

GlaxoSmithKline PLC

19 June 2017

Issued: Monday 19 June 2017, London UK - LSE

GSK confirms start date for Luke Miels

GSK has reached an agreement with AstraZeneca that Luke Miels will commence his appointment as President, Global Pharmaceuticals, GSK on 4 September 2017.

 
 GSK enquiries: 
 UK Media enquiries:   Simon Steel        +44 (0) 20    (London) 
                                           8047 5502 
                       David Mawdsley     +44 (0) 20    (London) 
                                           8047 5502 
 
 
 US Media enquiries:   Sarah Alspach      +1 202 715    (Washington, 
                                           1048          DC) 
                       Sarah Spencer      +1 215 751    (Philadelphia) 
                                           3335 
 
 
 Analyst/Investor      Sarah Elton-Farr   +44 (0) 20    (London) 
  enquiries:                               8047 5194 
                       Tom Curry          + 1 215 751   (Philadelphia) 
                                           5419 
                       Gary Davies        +44 (0) 20    (London) 
                                           8047 5503 
                       James Dodwell      +44 (0) 20    (London) 
                                           8047 2406 
                       Jeff McLaughlin    +1 215 751    (Philadelphia) 
                                           7002 
 
 
 
 
 
 
   GSK cautionary statement regarding forward-looking 
   statements 
 
 
   GSK cautions investors that any forward-looking 
   statements or projections made by GSK, including 
   those made in this announcement, are subject 
   to risks and uncertainties that may cause actual 
   results to differ materially from those projected. 
   Such factors include, but are not limited to, 
   those described under Item 3.D 'Principal risks 
   and uncertainties' in the company's Annual Report 
   on Form 20-F for 2016. 
 Registered in England & Wales: 
  No. 3888792 
 
 Registered Office: 
  980 Great West Road 
  Brentford, Middlesex 
  TW8 9GS 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCZMGMVKLNGNZM

(END) Dow Jones Newswires

June 19, 2017 11:29 ET (15:29 GMT)

1 Year Gsk Chart

1 Year Gsk Chart

1 Month Gsk Chart

1 Month Gsk Chart

Your Recent History

Delayed Upgrade Clock